← Leaderboards
Alireza Mansouri
Pennsylvania State Univ Hershey Med Ctr
$1,394,422
Attributed
$1,394,422
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $638.8K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,394,422 · 2
By mechanism
R01$1,253,576 · 1
R03$140,846 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Tumor”
- Kenneth Schultz · Trethera Corporation$7,146,643
- Jeff P Simko · Washington University$4,848,843
- Gary G Schwartz · University Of North Dakota$4,000,000
- Yicheng Wang · Immunova Therapeutics, Llc$4,000,000
- David G Brooks · Boston Immune Technologies And Therapeutics, Inc.$3,974,764
- Daniel Francis · Claria Medical, Inc.$3,708,259
Research focus
TumorGliomaGlioblastomaSuccessAffectLiquid SubstanceExcisionFutureMass Spectrum AnalysisSamplingTumor TissueBloodPathway InteractionsOperative Surgical ProceduresAdultClinical TrialsBrain NeoplasmsFda ApprovedBlood-Brain Barrier DisruptionBlood - Brain Barrier AnatomyApoptosisCentral Nervous System LymphomaBiomarker ValidationAntitumor Effect
Grant awards (4)
Integration of CSF Proteogenomics in the Diagnosis and Management of Diffuse Gliomas$614,772
R01 · FY2025 · CA · contact PI
Integration of CSF Proteogenomics in the Diagnosis and Management of Diffuse Gliomas$638,804
R01 · FY2024 · CA · contact PI
Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial$70,423
R03 · FY2023 · CA · contact PI
Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial$70,423
R03 · FY2022 · CA · contact PI